| Accession |
PRJCA024371 |
| Title |
An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937, as Monotherapy or in Combinations With JNJ-61186372 |
| Relevance |
Medical |
| Data types |
Genome sequencing and assembly
|
| Organisms |
Homo sapiens
|
| Description |
This is An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ 61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer |
| Sample scope |
Multiisolate |
| Release date |
2024-03-16 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Janssen Research & Development, LLC
|
|
2023LB00239/2023LB00240
|
|
|
|
| Submitter |
yongsheng
wang (wysdoc756@163.com)
|
| Organization |
West China Hospital of Stomatology, Sichuan University |
| Submission date |
2024-03-16 |
